The paradox of direct-acting anticoagulants in peripheral arterial disease in Spain

Q: What is the clinical evidence from this study?

Study design: Review. Population: Venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Intervention: New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Conventional anticoagulants (Vitamin K antagonists, LMWH).

Q: What does this research mean for the field?

New oral anticoagulants such as dabigatran and rivaroxaban offer fixed oral dosing without the need for routine monitoring, potentially replacing conventional anticoagulants in various indications including peripheral arterial disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Carlos Esteban Gracia

doi:10.20960/angiologia.00638

January 1, 2024AngiologíaOpen Access

The paradox of direct-acting anticoagulants in peripheral arterial disease in Spain

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

I

Intervention

New oral anticoagulants (direct thrombin inhibitors such as dabigatran etexilate, and direct factor Xa inhibitors such as rivaroxaban and apixaban)

Limitations

Lack of specific antidotes for the new oral anticoagulants
Lack of efficacy and safety data in patients with renal or hepatic insufficiency, and pregnant women
Higher initial cost compared to low molecular weight heparins
Lack of a specific antidote
Lack of efficacy and safety data in patients with renal failure, hepatic failure, or pregnant women

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

New oral anticoagulants represent a significant pharmacological advancement by providing predictable pharmacokinetics without routine monitoring, though their definitive role across all indications requires further clinical validation.

Abstract

Angiología es una revista científica bimensual editada desde 1949. Está dedicada al estudio de las enfermedades vasculares, incluyendo todos los aspectos de la medicina vascular, el diagnóstico no invasivo, el tratamiento quirúrgico tradicional arterial y venoso, así como el mínimamente invasivo y/o endovascular.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Carlos Esteban Gracia (2024) conducted a review in Venous thromboembolism, atrial fibrillation, and acute coronary syndrome. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Conventional anticoagulants (Vitamin K antagonists, LMWH) was evaluated.

synapsesocial.com/papers/6a1765b30a2f3f8e14127661 https://doi.org/10.20960/angiologia.00638

View Full Paper

Ask AI

Bookmark

Share

The paradox of direct-acting anticoagulants in peripheral arterial disease in Spain

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The paradox of direct-acting anticoagulants in peripheral arterial disease in Spain

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading